



COMPANY PROFILES
BIOMED 2013 - BIO DENMARK BOOTH NO 61

EMBASSY OF DENMARK
THE TRADE COUNCIL • EKSPORTRÅDET

COPENHAGEN
CAPACITY



Ministry of Science, Innovation
and Higher Education



Denmark

Dear Guest

As Danish Minister for Science, Innovation and Higher Education, it is my great pleasure to offer you the opportunity to explore Danish excellence in life sciences at IATI-Biomed.

The Danish delegation to IATI-Biomed consists of some of our most successful and innovative companies as well as highly acclaimed research institutions. The delegation is here to work towards increased international cooperation, to exchange knowledge and ideas and to establish new ways to improve medical knowledge and health care.

Danish expertise in life sciences and our ability to develop and market medical products ensure that Danish companies and institutions are attractive partners for counterparts from all over the world.

I am also very happy to be present at IATI-Biomed this year and to have the opportunity to experience Israel. Denmark and Israel have a lot to learn from one another in the field of life sciences. Both countries perform world class research, and there is a growing tradition for collaboration between our countries.

Danish-Israeli cooperation in life sciences has proven to be fruitful and our bilateral agreement on industrial research and innovation cooperation makes it possible for us to strengthen our ties even further.

On the following pages, you will find information on the companies and research institutions in the Danish delegation. If you find something of interest to you, please come to our booth, and we will be happy to assist you.

Yours sincerely,

Morten Østergaard
Danish Minister for Science, Innovation and Higher Education



Ministry of Science, Innovation and Higher Education of Denmark

ORGANIZERS

The Danish Ministry of Science Innovation and Higher Education promotes Danish companies and research institutions participation in Biomed 2013 in Tel Aviv. Denmark is known for its many highly qualified researchers and knowledge intensive SMEs. But we want to become even better. And for this we need international cooperation on Research and Innovation (R&I) within international programmes such as Eurostars and EUs new programme for research and innovation, Horizon 2020.

Being a small country the impact on growth and welfare of international Research and Innovation cooperation is even more profound because only 1.5% of worlds total investment in R&I is invested in Denmark. To get access to advanced fields of science and technology Danish companies and research institutions must cooperate internationally.

Why engage in international market oriented R&I cooperation?

Cooperation on R&I is important for knowledge generation. Both for industry and academia. A Danish impact study has shown that companies investing in R&I cooperation are on average 15% more productive than companies that do not. Productivity and growth are even greater in companies that collaborate internationally on R&I in international programmes such as EUREKA/Eurostars:

- International cooperation on R&I increases turnover:
Participants in EUREKA projects increase growth rates in turnover twice as much, compared to businesses not participating in international R&I cooperation.
- International cooperation on R&I increases export:
Participants in EUREKA projects increase growth rates in exports with 13 pct. points more than participants in national projects.
- International cooperation on R&I increase employment:
Participants in EUREKA projects increase growth rates in employment significantly in several years after the conclusion of the project.
- International cooperation on R&I increases productivity:
Participants in EUREKA projects increase growth rates in labour productivity 11-12 pct. points more than participants in national projects.

contact:

Jens Peter Vittrup
Special Consultant
t: +45 25 18 66 01
e: jpv@fi.dk
www.fivu.dk



Ministry of Science, Innovation
and Higher Education

ORGANIZERS

The Royal Danish Embassy, Israel

contact:

Lasse Holm Grønning
Commercial Advisor
t: +972 3 60 85 871
e: lasgro@um.dk
www.israel.um.dk

The Department of Trade and Innovation of the Royal Danish Embassy in Tel Aviv is a part of the Danish Trade Council – an integrated part of the Ministry of Foreign Affairs of Denmark.

The Trade Council assists Danish companies with export and internationalization, as well as foreign companies considering business opportunities in Denmark.

One of our missions is to service Danish and Israeli companies considering the possibility of cooperation through active, focused marketing efforts.

The overall goal of our department is to strengthen the globalization of Danish business and increasing the level of competence and knowledge as well as relations between Denmark and Israel.

DANISH EMBASSY TEL AVIV



Copenhagen Capacity

Copenhagen Capacity is the Danish Capital Region's official inward investment agency. The mission of Copenhagen Capacity is to promote the region internationally with the aim of attracting and maintaining foreign companies.

Copenhagen Capacity possesses a dedicated team of consultants who provide free of charge services, information and personal assistance to foreign investors considering Greater Copenhagen as a possible location for future activities.

Copenhagen Capacity is placed in the middle of Scandinavia's Life Science Centre, Medicon Valley.

More than 350 medtech, biotech and pharma companies are sited in Medicon Valley. Medicon Valley has a strong pool of Universities and very strong technology transfer from these to the companies. The amount of talented and well educated people is vast in Medicon Valley, because of the many universities and effective Danish education system.

Copenhagen offers a great place to live and work with free schools, free healthcare and easy access to childcare. Copenhagen Capacity can help establish contact to the region and assist you in setting up a business in Medicon Valley.

ORGANIZERS

contact:

Espen Gregersen
t: +45 33 26 87 29
m: +45 29 40 27 44
e: egr@copcap.com
www.copcap.com

COPENHAGEN
CAPACITY

Ampliqon A/S

contact:

Helle N.Thestrup, Ph.D
Managing director
t: +45 70 20 11 69
m: +45 66 10 61 30
e: hnt@ampliqon.com
www.ampliqon.com

Ampliqon IIII
Bioreagents & PCR Enzymes

Who we are:

Ampliqon A/S is a Danish manufacturer of DNA polymerases, PCR products and chemical reagents. Founded in 2002 as an innovative enzyme manufacturer, the company has expanded its production to comprise chemical reagents as well and is now producing more than 1000 different reagents. Ampliqon produces high quality DNA polymerases for hospitals, research institutions and life-science industries all over the world.

Ampliqon produces quality PCR products for both routine PCR, real time PCR and high fidelity applications.

Ampliqon is a highly flexible company and has great focus on making custom-made solutions and products. In recent years, we have developed a number of unique solutions on the demands of our PCR-using customers, e.g. a glycerol free Taq polymerase optimized for automation.

Why are we participating in BioMed 2013:

Ampliqon would like to extend its network of international contacts among new distributors, customers for direct sales or partners for scientific/commercial collaboration.

What we are looking for:

New customers for our PCR products and chemical reagents
Customers with a need for custom-made PCR products and chemical reagents.

New distributors of our products for markets outside Denmark
Collaboration partners for development of new products and know-how.

Aneeva Ltd.

COMPANIES

Who we are:

Aneeva Ltd. provides Business Acceleration Services in European markets and Israel through direct and channel sales.

Aneeva works as sales representatives, agents or consultants within the BioMed, Clean&WaterTech, IT & Tele and Defence sectors.

More than 50 companies have used our services successfully in the past 8 years, with a success rate of 76% and an accumulated sales volume nearing the €100M mark. Projects run from a few months to several years.

Together with the Market Penetration services, Aneeva also offers Technology Scouting, Market Estimation and funding (non Equity grants) services. These services include besides the discovery and flourishing of relevant technologies, consultancy in non-Equity funding and granting between organisations and countries.

Why we are participating in BIOMED 2013:

In order to assist companies or organisations who are interested in entering the life science sector in Denmark as well as in Israel. Suggested assistance: Local sales representatives or agents in Denmark/Scandinavia and in Israel, helping to penetrate the market. To offer our technology scouting services within the life science sector in Israel.

What we are looking for:

We are looking for companies and organizations who:

- Need assistance with grant preparation, evaluation & management. (EU, US, IL)
- Require technology scouting in Israel
- Would like to penetrate their products to Europe and/or Israel

contact:

Gideon Silberman

Director

Business Development

t: +45 54 62 40 88

m: +972 54 30 82 089

f: +972 77 51 55 024

e: gideon@aneeva.com

www.aneeva.com



BioModics ApS

contact:

Peter Thomsen
CEO
m: +45 61 66 66 19
e: pt@biomodics.com
www.biomodics.com

The logo for BioModics features the word "BIO" in a dark teal color, followed by a stylized orange and white globe icon, and then the word "MODICS" in the same dark teal color.**Who we are:**

BioModics ApS develops innovative solutions for silicone based medical devices using SiliCO2ne Impregnation™ technology. This technology is used to create a nano network in silicone rubber. This network can be used as a combined storage and controlled delivery system for drugs. A wide range of drugs for long time delivery can be used. This can result in new solutions within segments such as implants, catheters, stents, wound care, diagnostics, packaging and switches. BioModics takes on projects to meet partner requirements. In most of our projects we aim to transfer IP to the customer.

Our technology platform supports the release of drugs, such as antibacterial drugs for wound care and catheters. It is unique because it allows drugs to be stored and released over a long period of time.

Why are we participating in Biomed 2013:

We have chosen to participate in BioMed because of its high number of innovative companies. We see this is a good starting point for collaborations.

What are we looking for:

We are looking for potential collaborators who can help us further develop BioModic's technology platform. We are interested in outlicensing our technology.

Bioneer A/S

COMPANIES

Who we are:

Bioneer is a medium sized Danish company that provides a range of research based services for biomedical, pharmaceutical and biotechnological companies. Bioneer is a non-profit organisation owned by the Technical University of Denmark and is part of the Danish Advanced Technology System.

Why we are participating BIOMED 2013:

To create novel contacts within our R&D areas.

To assist the Danish Agency for Science Technology and Innovation in bridging and creating collaboration contacts between Israeli and Danish biotech, biomedical and medico companies.

What we are looking for:

Parties interested in Bioneer's service portfolio in biomedicine, including

- Protein manufacturing
Protein manufacturing process development (microbial, mammalian hosts, GMP-ready)
- Pharmaceutical development
Predictive gastro intestinal wet-lab models (stomach, intestine) simulating the human GI system. Barrier models including the intestine, kidney, lung and brain. Predictive Immune models. Formulation of biologics and small molecules using liposomes, emulsions, SNEDDS and other drug delivery systems. Age appropriate drug delivery systems (children and the elderly)
- Stem Cell Technology
Creation of reprogrammed stem cells from patients. Manufacturing of iPS cells, Development of patient specific disease models
- Biomarker technology
High throughput molecular histology platform. Specialized in breast and colon cancer.

contact:

Lars H. Pedersen, Ph.D.
Director R&D
t: +45 45 16 04 44
m: +45 24 60 63 52
f: +45 45 16 04 55
e: lap@bioneer.dk
www.bioneer.dk

The logo for Bioneer, featuring the word "bioneer" in a blue, lowercase, sans-serif font. The letter "e" is stylized with a horizontal line through its middle, and the "r" has a unique, blocky design.

ChemPartner Europe ApS

contact:

Peter Halkjaer-knudsen
Executive director
t: +45 45 86 90 00
m: +45 40 12 37 47
f: +45 45 86 90 14
e: peterhk@chempartner.cn
www.chempartner.cn



ChemPartner Europe ApS. is the EU subsidiary of Shanghai ChemPartner Company Ltd. (ChemPartner).

We participate in BioMed as a service provider, making high-end scientific research available to both pharma and biotech. We have good collaborations already established here in Israel.

ChemPartner is a leading contract research organization providing full service drug discovery, development and pharmaceutical manufacturing capabilities to its clients across the globe for both antibodies and small molecules. ChemPartner provides its customers and partners with fully integrated R&D services including chemistry, biology, pharmacology, DMPK, process R&D, pre-formulation, formulation, CMC and analytical development. With an established client base of above 240 Pharma and Biotech companies within drug discovery and development, ChemPartner has since 2002 demonstrated our capabilities in meeting goals, timelines and budgets.

ChemPartner has a broad variety of services within drug discovery: Biology from assay development, expression in cell lines, in vitro and in vivo screening in assays and animal models within the therapeutic areas of CNS, oncology, metabolic and cardiovascular diseases, infectious diseases, inflammation and immunology. Chemistry has the traditional area of expertise with synthesis from mg to ton scale, medicinal chemistry, library production supported by computer modeling, analytical R&D services, non-GLP and GLP bioanalysis, biologics R&D, ADME/DMPK, non-GLP toxicology.

Ecron Acunova A/S

COMPANIES

Who we are:

Ecron Acunova is an international CRO with widespread and strong representation in Denmark, Scandinavia, Western Europe, as well as own offices and dedicated staff in Eastern Europe. We have a strong presence in Asia and are established in USA.

In Scandinavia, we originated in Denmark more than 40 years ago, and still have our Nordic headquarter in Denmark, with offices in Sweden and Finland.

Ecron Acunova has specific experience in clinical studies from Phase I to Phase III, BA/BE and PK/PD studies, as well as Investigator Initiated studies. In close collaboration with our Scandinavian University Institutions and other large hospitals, we offer the highest quality to our clients and sponsors. Similar relations to institutions and hospitals can be offered in other parts of the world where we operate. In USA, we have a comprehensive collaboration with all major cancer clinics, hereunder the many private clinics which are so important for patient recruitment in USA.

We listen to our customer and create smart tailor-made solutions from our full-service CRO offering. Everything from study design to final study report is offered. We work with the latest technologies in order to increase quality and efficiency. Our lean organization enables us to be competitive from a cost point of view.

We cherish our dedicated and highly qualified Nordic team of employees, and with our operational excellence, few companies can offer better expertise and services within clinical trials.

Why we are participating in BIOMED 2013:

To establish Israeli and international contacts to companies, who are about to embark in clinical studies or who already are in the clinical-stage.

What we are looking for:

We are looking to build relations with innovative development companies who have an interest in exploring clinical trial opportunities in Denmark, Scandinavia or in other locations.

contact:

Helen Schierbeck-Hansen
Director, Business Development
t: +45 45 16 88 00
m: +45 61 55 80 99
e: helen.schierbeck-hansen@ecronacunova.com
www.ecronacunova.com



epiZell ApS

contact:

Steen Pontoppidan
CEO
m: +45 40 40 45 01
e: sp@epizell.com
www.epizell.com

**Who we are:**

epiZell offers a wide range of analytical mass spectrometric services, including structure elucidation, metabolic studies, development and validation of LC-MS and LC-MS/MS methods. We also provide training courses in mass spectrometry.

In addition we work on two development project:

- **Ligand-screening:** Development of a device for investigations of molecular recognition. The device is based on electrocapture and potentially enables the screening of drug candidates in a solvent stream without chemical modifications of the receptor and without advanced robotics.
- **Biomarker analysis:** We are developing an exceptionally sensitive platform based on protein microarrays and the use of Secondary Ion Mass Spectrometry (SIMS) in the detection. Multiplexed analyses of e.g. cytokines in very small sample volumes is possible on the platform. The high sensitivity and low sample requirements of the method are notably significant in preclinical development and in the clinical management of cancer, rheumatological conditions and premature babies.

Why we participate in BioMed 2013:

We want to market our analytical services and meet potential investors and collaborators for our development projects.

What we are looking for:

- Customers for our analytical services.
- Investors for development of our ligand-screening platform.
- Investors or collaborators for development and validation of our analytical platform for biomarkers.

Expres2ion Biotechnologies

COMPANIES

Who we are:

Development of efficient platforms for production of recombinant proteins is essential in modern approaches to disease prevention and therapy. In the last 15 years, Drosophila Schneider-2 (S2) cells systems for recombinant protein production have advanced to cGMP manufacturing for clinical development. Recombinant proteins made in S2 cells have been tested in clinical phase I and 2 trials. Strengths of this non-viral, non-lytic system: relative production speed, fast access to the required proteins, excellent expression capability, scalability and regulatory friendliness.

Expres2ion Biotechnologies, based in Horsholm Denmark, was founded in 2010 to serve the vaccine and biotherapeutics needs for challenging proteins. The founding team has optimised the S2-based system for more than 13 years to enable expression of proteins, from R&D to cGMP.

The proprietary ExpreS2 platform includes a cell line, expression vectors, transfection reagent, optimised culture media and know-how to use these components. Proteins are expressed in S2 cells at high levels, authentically processed and biologically active.

Why are we participating in BioMed 2013:

BioMed offers the opportunity to interact with innovation and product development actors within the medical and pharmaceutical areas.

What are we looking for:

Raise awareness to the advances that ExpreS2ion has enabled in projects where protein expression was a critical need; find new customers and applications for the ExpreS2 platform and for our services; make contacts with relevant top level academic teams.

contact:

Sancha Salgueiro, Ph.D. MBA
Vice President Business Development
t: +45 41 66 61 21
e: sas@expres2ionbio.com
www.expres2ionbio.com

EXPRES²ION
BIOTECHNOLOGIES

Meabco A/S

contact:

Stig Lofberg
CEO

t: +45 32 46 03 70

e: stig.lofberg@meabco.com

www.meabco.com



Who we are:

Meabco is a clinical stage Biotech Company focused on cancer and anti-radiation therapy. It is using its BP-Cx-I technology platform to develop a portfolio of innovative products targeting disease and conditions with high unmet medical needs and a larger market potential.

The Company's lead product, BP-CI, is currently undergoing clinical trials in patients suffering from advanced metastatic breast and pancreas cancer.

Why we participate in BioMed 2013:

Meabco A/S participates in BioMed in order to identify and discuss possible collaboration with potential Israeli partners in:

1. Non-clinical trials and clinical trials in various cancer types as well as discussing commercial opportunities with relevant entities.
2. Non-clinical trials and clinical trials in various anti-radiation aspects.

What we are looking for:

Scientific institutions and private enterprises with expertise in:

- Cancer
- Anti Radiation
- Health Economics
- Regulatory Affairs.

Niels Clauson-Kaas A/S

COMPANIES

Who we are:

Niels Clauson-Kaas A/S (NCK) was founded in 1956 to conduct research and development in synthetic organic chemistry on a contract basis. NCK has worked for more than 180 customers world-wide. Most of the products which NCK develop are APIs for pre-clinical or clinical studies and are produced in accordance with cGMP. NCK routinely develops and validates analytical methods for release testing of APIs. Important core values are timely delivery, quality and communication.

In 2011 NCK entered into collaboration with OncoTargeting AB (Sweden), and together the companies are able to offer services ranging from early discovery chemistry and process development to supply APIs throughout clinical phases II/III. The companies also offer CMC project management, pre-formulation, radiolabelling, in-vitro services and autoradiography studies.

Why we are participating in BioMed 2013:

NCK is participating with the intent of identifying small to medium sized biotech companies who need a strong partner for making small molecule APIs for pre-clinical and clinical trials, preparing a solid CMC strategy, as well as related services, e.g. discovery, small scale synthesis and radiolabelling.

What we are looking for:

NCK is looking for contacts and potential biotech collaborators in Israel, who have a need for small molecule process development and API manufacture throughout the development phase (pre-clinical to PII/PIII clinical trials) in their drug development program.

contact:

Jorgen Godt Olsen
Executive Vice President
t: +45 44 95 18 81
m: +45 22 44 44 39
f: +45 44 95 18 55
e: jgo@clauson-kaas.dk
www.clauson-kaas.dk



Novamed

contact:

Ulrich Rothaus Andersen
Managing Director
m: +45 27 50 68 06
e: ura@novamed.dk
www.novamed.dk

novamed 

Who we are:

Novamed is a small privately owned Danish company. In collaboration with Copenhagen University Hospital, (Rigshospitalet) we have developed a unique contrast delivery system for Computed Tomography (CT). The system offers not only significant cost savings over current methods but also saves time enabling higher patient throughput. The innovative contrast delivery system features several validated check valves as well as a unique filter making the system safe with no risk of cross contamination between patients.

The rate of CT examinations within OECD countries varies from 60 to 325 per 1,000 people averaging 139 and suggesting nearly 170 million CT examinations per year (OECD Health Data June 2010).

Why are we participating in Biomed 2013:

Having participated in 2011 where we made good relations and witnessed the benefits of being part of the Danish BIOMED delegation we are now looking forward to this year's conference.

What are we looking for:

We are looking for potential collaboration partners to further develop our product as well as business angels.

Novo Nordisk A/S

COMPANIES

Who we are:

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Why we participate in BioMed 2013 and what we are looking for:

We believe success is in partnerships: Although we are experts in focused R&D areas, we also recognize the importance that partnering can play in securing successful pipeline development.

No company will be able to sustain innovation without strategic collaborations with external partners, both in academia and industry.

Headquartered in Denmark, Novo Nordisk employs approximately 34,700 employees in 75 countries, and markets its products in more than 180 countries.

contact:

Guy Gorecki
Market Access &
Public Affairs Director
t: +972 976 304 44
e: gugo@novonordisk.com
www.novonordisk.com



Nuevolution A/S

contact:

Mads Norregaard-Madsen
Ph.D., Chief Innovation &
Information Officer
t: +45 39 13 09 10
m: +45 22 78 97 60
e: mn@nuevolution.com
www.nuevolution.com

**Who we are:**

Nuevolution's Chemetics® technology brings a quantum leap to small-molecule lead discovery.

Today, several technologies including HTS, HCS and fragment based screening, are applied both simultaneously and consecutively worldwide by big pharma and biotech companies to offer medicinal chemists a better strategy for identification of leads with optimal properties.

Nuevolution's Chemetics® technology unifies the best of high throughput screening and fragment-based screening, sampling millions to billions of fragments.

In the screening process a target of interest is exposed to a mixture of 100 million molecules. From this mixture, the target will select those molecules with the appropriate ligand characteristics based on Nature's evolutionary principles: The better properties – The higher chance of survival.

As in Nature, DNA embodies the enabling vehicle allowing Nuevolution to work in nano scale using multi-millions of compounds in complex mixtures. Each compound within a Chemetics® library is linked to a strand of DNA encoding the synthetic history and chemical structure of the small molecule.

Nuevolution applies the Chemetics® to biological targets of pharmaceutical importance in partnerships with pharmaceutical partners (Merck & Co, Novartis, Lexicon, Boehringer-Ingelheim) and internal research.

Currently, Nuevolution has a portfolio of internal pipeline program targets within cancer, inflammation, metabolic disorders and epigenetics.

Why we are participating in BIOMED 2013:

We wish to identify additional collaboration and joint venture opportunities.

What we are looking for:

We are interested in meeting with potential collaborators with projects where state-of-the-art small molecule screening is needed.

ORIGIO A/S

COMPANIES

Who we are are:

ORIGIO is the world leader, in terms of market share and innovation, within the highly attractive market for “assisted reproduction technology” (ART), based on a 25 years’ track record in fertility treatment.

ORIGIO is offering the broadest assortment today, addressing the market with the necessary liquid media, micropipettes as well as other related disposables and IVF equipment

ORIGIO is a Danish company with headquarter in Copenhagen area but with a strong global presence. Global markets are addressed directly in +25 countries, whereas an additional +100 markets are served through an extensive distributor network.

ORIGIO has around 350 employees from which 120 are positions in Denmark. Starting from 2012 ORIGIO has become integrated with CooperSurgical, part of US healthcare group The Cooper Companies.

ORIGIO operates with manufacturing sites in Denmark, USA and The Netherlands.

Our Vision: To make the #1 dream of every infertile couple comes true

Our Mission: We deliver leading, innovative ART solutions to the benefit of families

Why are we participating in BioMed 2013:

We have chosen to participate in BioMed 2013 because Israel is a leading country within life science and innovation and more specifically with our field of ART. BioMed is an interesting platform to expose ORIGIO towards the Israeli market as an innovative operator and manufacturer.

What are we looking for:

We aim to strengthen our customer relations and to address current and future collaborators in order to optimize our business performance in Israel.

contact:

Simon Kvetny
Export Manager
t: +45 40 30 86 52
e: skvetny@origio.com
www.origio.com

The logo for ORIGIO, featuring the word "origio" in a lowercase, purple, sans-serif font. The letter 'i' has a unique design with a dot that curves around the top of the letter.

a CooperSurgical Company

contact:

Ulf B. Christensen
CEO
t: +45 36 96 94 96
m: +45 27 10 21 51
e: ubc@pentabase.com
www.pentabase.com



Who we are:

PentaBase is providing tools and solutions for genetic analysis and diagnostics. We were founded in 2006 based on a proprietary DNA platform technology. Using this platform technology in our products, makes us capable of providing cutting edge genetic research and diagnostic tools, including the world's best performing primers and probes for Real-time PCR.

We supply researchers as well as hospitals and companies with assays for the sensitive and specific determination of genetic states after their wishes and desires.

We have, furthermore in house, developed RUO assays for detections of various SNPs and somatic mutations.

Why are we participating in BioMed 2013:

PentaBase is looking for hospitals and companies interested in detection of somatic mutations, for example the detection of mutations in KRAS, BRAF, etc. We are also interested in scientists who use PCR and/or real-time PCR, to offer them primers, probes and services at unbeatable prices and quality.

What are we looking for:

We are especially interested in co-developing assays and procedures using our novel technologies and your expert knowledge in your field.

We are always open for talks with business angels and other potential investors.

Treat Systems ApS

COMPANIES

Who we are:

Worldwide studies show that approx. 40% of all patients with infectious diseases receive inappropriate antibiotic treatment resulting in unnecessary deaths and prolonged hospitalization. At the same time, partly due to superfluous or inappropriate prescription of antibiotics, bacterial resistance to antibiotics has become a life-threatening problem. If left unaddressed, this will result in an increasing number of unnecessary deaths and bed-days.

Treat Systems has developed TREAT - a personalized infectious disease treatment system designed to support physicians in prescribing appropriate treatment, while reducing the ecological costs of future drug resistance.

Clinical trials with more than 6.000 patients worldwide show that TREAT significantly increases prescription of covering treatment and improves infectious disease treatment on a highly attractive cost/benefit basis to hospitals, physicians, and patients.

Why we are participating in BIOMED 2013:

We are here to finalize and sign contracts for the installation of TREAT at two Israeli university hospitals and to introduce TREAT to other hospitals and/or companies.

What we are looking for:

We are seeking hospitals interested in improving infectious disease treatment and at the same time maintaining antibiotic stewardship.

contact:

Bjarne Kristensen
Sales Manager
m: +45 25 34 34 20
e: bk@treatsystems.com
www.treatsystems.com



ViroGates A/S

contact:

Helle Fisker
VP Sales & Marketing
t: +45 36 98 06 45
m: +45 29 17 87 77
e: hf@virogates.com
www.virogates.com

**Who we are:**

ViroGates A/S is an international Diagnostic company headquartered in Denmark, north of Copenhagen, in the heart of Medicon Valley. ViroGates owns the rights for detection of the risk stratifying biomarker suPAR in blood, and has recently commercialized a CE-marked product line called suPARnostic® containing a Point-of-Care and an ELISA assay for more accurate detection.

Based on more than 10 years of clinical evidence it is clear that the suPAR biomarker has the potential to be used as an adjunctive test in the Emergency Room to add information about disease severity of the medical patient and to allow for a more accurate way to determine, which patients really need to be admitted to the hospital or not. Addressing a problem, which is apparent across hospitals all over the world ViroGates is convinced that the suPAR Biomarker test has a worldwide application potential, which with the right partners, is ready to be realised.

Why we are participating in BIOMED 2013:

To explore local and international collaboration opportunities in Israel for commercial and research purposes. Given the very strong international leadership Israel is showing in the field of innovation and life science, ViroGates believes in the expanded value of showcasing its technologies in the Israeli life science hub.

What we are looking for:

Investors, commercial partnerships and research partners.

Center for Biosustainability, DTU

NETWORKERS and
RESEARCH INSTITUTIONS

Who we are:

The Novo Nordisk Foundation Center for Biosustainability (CFB) is part of the Technical University of Denmark (DTU). CFB works in the field of engineering, design and construction of superior production hosts of biological pharmaceuticals (CHO cells), key organic compounds and green chemicals (E. Coli, Bakers Yeast and Streptomyces).

For optimal results state of the art technologies in the area of metabolic engineering, genome-scale science and in silico modelling are used. To perform the best industrial partnership CFB are focused on the current industry leaders needs related to deliveries from CFB's new platform technologies.

Why are we participating in Biomed 2013:

To find new international partners for future activities.

What are we looking for:

To establish new contacts in Israel and in the rest of the world.

contact:

Dorte Wissing Kaznelson
Business Development Manager
t: +45 45 25 80 00
m: +45 20 12 49 27
e: dowika@biosustain.dtu.dk
www.biosustain.dtu.dk



Centre for Innovation and Research The Capital Region of Denmark

contact:

Susie Andersen Ruff
Head of Innovation, Business
Development and Strategy
t: +45 40 83 96 37
m: +45 40 83 96 37
e: susie.andersen.ruff@regionh.dk
www.regionh.dk/vif



The Capital Region
of Denmark

Who we are:

The Capital Region of Denmark is one of five administrative units in Denmark. The region provides healthcare, mental healthcare and regional development for 1.7 million people or approx. 30% of the population of Denmark, in addition to doing research and innovation. The Region is responsible for ten large hospitals, amongst others the University Hospital of Copenhagen. The region employs 40,000 people – mainly health care professionals – making it one of Denmark's largest employers

Why are we participating in Biomed 2013:

Centre for Innovation and Research (CIR) acts as a point of entry for issues relating to innovation and research and the commercialisation hereof in the Capital Region of Denmark. The centre actively leads projects to commercialise inventions and advises on clinical trials and funding. It also carry out counselling and negotiation of contracts. CIR also deals with strategic and political issues pertaining to innovation and research. The Centre employs 35 highly specialised experts in Life Sciences, innovation methodology, commercialisation and funding.

What are we looking for:

- Technology transfer units globally in order to exchange experience, best practice and ideas
- Industry specific research within Life Science or MedTech areas
- Latest knowledge and trends in Bio.

Department of Pharmacy University of Copenhagen

NETWORKERS and
RESEARCH INSTITUTIONS

Who we are:

The Department of Pharmacy at the University of Copenhagen attempts to identify unmet needs in drug delivery and to develop solutions for them. In particular, oral formulations for children and the elderly, also addressing polypharmacy.

Why we are participating in BioMed 2013:

To assist the Danish Ministry of Science, Innovation and Higher Education in bridging and creating collaboration contacts between Israeli biomedical and medico companies and the University.

What we are looking for:

Interested parties to the Department's service portfolio within pharmaceuticals and pharmaceutical development:

- Predictive gastro intestinal wet-lab models (buccal, stomach, intestinal) simulating the human biological system
- Predictive barrier models including the intestine, kidney, lung and brain)
- Predictive Immune models
- Formulation of biologics and small molecules using liposomes, emulsions and SNEDDS
- Physical delivery technology

contact:

Daniel Bar-Shalom

Associate Professor

t: +45 35 33 63 51

m: +45 26 84 61 33

e: daniel.barshalom@sund.ku.dk

www.farma.ku.dk



FACULTY OF HEALTH AND MEDICAL SCIENCES
UNIVERSITY OF COPENHAGEN

EUREKA / Eurostars

Read more:

Economic Impact of International Research and Innovation Cooperation – Analyses of 25 years of Danish participation in EUREKA.
www.eurekanetwork.org/document_library/




EUREKA was started as a European industrial oriented initiative in 1985 and has since then generated more than 4000 market oriented R&I projects.

In 2007 the SME oriented Eurostars Programme was launched as a joint programme between EUREKA member states and the EU Commission. It is a special feature of Eurostars that it focuses on R&I intensive SMEs. They have to contribute with at least 50% of the workload in any Eurostars project. 70% of all Eurostars participants are SMEs and 23% are research institutions.


Eurostars will continue in the European research programme Horizon 2020 from 2014 to 2020. The total funding budget of Eurostars is expected to be around 1.2 billion €. An estimated 1,200 applications will be forwarded annually of which 250-300 projects will be funded.

Eurostars allows SMEs to lead international collaborative R&I projects on a minimum of two countries, two partners basis. 33 EUREKA member states participate in Eurostars today. It is expected that the number of member states will grow from 2014 including Canada and South Korea, which are participating in EUREKA as associated member states.

Organisation types:
Eurostars



Market areas by number of projects:
Eurostars



10 Reasons

For choosing Denmark for R&D and Business Activities:

- 1. Unique framework conditions for the pharmaceutical industry**
- 2. Denmark ranks 2nd internationally by the number of publications based on clinical trials and pharmaceutical research**
- 3. Tradition for close public-private partnerships**
- 4. State investments in public-private research partnerships**
- 5. Highly qualified labour**
- 6. Heavy investment in new research infrastructure creates unique frameworks for pharmaceutical research in Denmark**
- 7. World-class patient registries, civil registries and biobanks**
- 8. The best clinical trial subjects**
- 9. Health service of high international standard**
- 10. Efficient public authorities**

